Exhibits endothelin receptor activity and type 1 angiotensin receptor binding activity. Involved in several processes, including enteric nervous system development; positive regulation of penile erection; and regulation of blood vessel diameter. Localizes to the membrane raft; nuclear membrane; and plasma membrane. Used to study several diseases, including artery disease (multiple); lymphopenia; megacolon (multiple); portal hypertension; and sensorineural hearing loss. Biomarker of asthma; hepatopulmonary syndrome; and hypertension. Human ortholog(s) of this gene implicated in ABCD syndrome; Hirschsprung's disease; Waardenburg syndrome type 4A; Waardenburg's syndrome; and asthma. Orthologous to human EDNRB (endothelin receptor type B); PARTICIPATES IN calcium/calmodulin dependent kinase signaling pathway; endothelin signaling pathway; inflammatory response pathway; INTERACTS WITH (R)-noradrenaline; (S)-colchicine; (S)-nicotine.
[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine, [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]], EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
bisindolylmaleimide I inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein], bisindolylmaleimide I inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA
7-nitroindazole inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein], 7-nitroindazole inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein], 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA more ...
CPU0213 inhibits the reaction [Isoproterenol results in increased expression of EDNRB mRNA], natakalim inhibits the reaction [Isoproterenol results in increased expression of EDNRB protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein], N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]
Nitroprusside inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein], Nitroprusside inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA, Atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]
SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA], SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB protein]
[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA, atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]
Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA], Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
Freund's Adjuvant inhibits the reaction [Urethane results in decreased expression of EDNRB mRNA], IFNG protein inhibits the reaction [Urethane results in decreased expression of EDNRB mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
mutation of this gene in humans a leads to congental aganglionic megacolon or Hirschsprung disease, participates in deoxycorticosterone acetate (DOCA)-salt-induced hypertension, cardiovascular hypertrophy and renal damage
mutation of this gene in humans a leads to congental aganglionic megacolon or Hirschsprung disease, participates in deoxycorticosterone acetate (DOCA)-salt-induced hypertension, cardiovascular hypertrophy and renal damage
mutation of this gene in humans a leads to congental aganglionic megacolon or Hirschsprung disease, participates in deoxycorticosterone acetate (DOCA)-salt-induced hypertension, cardiovascular hypertrophy and renal damage
expressed in vascular and nonvascular tissues of the lung, brain and gut, mRNA first detected in the neural crest cells and in the wall of the forgut diverticulum.
expressed in vascular and nonvascular tissues of the lung, brain and gut, mRNA first detected in the neural crest cells and in the wall of the forgut diverticulum.
expressed in vascular and nonvascular tissues of the lung, brain and gut, mRNA first detected in the neural crest cells and in the wall of the forgut diverticulum.
Gene-Chemical Interaction Annotations
